Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges - PubMed (original) (raw)

Review

. 2008 Aug;22(9):1064-70; discussion 1075, 1080-1, 1084.

Affiliations

Review

Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges

James W Hodge et al. Oncology (Williston Park). 2008 Aug.

Abstract

The combination of radiation therapy and immunotherapy holds particular promise as a strategy for cancer therapeutics. Evidence suggests that immunotherapy is most beneficial alone when employed early in the disease process or in combination with standard therapies (eg, radiation) later in the disease process. Indeed, radiation may act synergistically with immunotherapy to enhance immune responses, inhibit immunosuppression, and/or alter the phenotype of tumor cells, thus rendering them more susceptible to immune-mediated killing. As monotherapies, both immunotherapy and radiation may be insufficient to eliminate tumor masses. However, following immunization with a cancer vaccine, the destruction of even a small percentage of tumor cells by radiation could result in crosspriming and presentation of tumor antigens to the immune system, thereby potentiating antitumor responses. Learning how to exploit radiation-induced changes to tumor-cell antigens, and how to induce effective immune responses to these cumulatively immunogenic stimuli, is an exciting frontier in cancer therapy research. This review examines mechanisms by which many forms of radiation therapy can induce or augment antitumor immune responses as well as preclinical systems demonstrating that immunotherapy can be effectively combined with radiation therapy. Finally, we review current clinical trials where standard-of-care radiation therapy is being combined with immunotherapy.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Antigen release from dying tumor cells can activate immune responses. Irradiation induces death of cancer cells. As these cells die, they are taken up by scavenger cells called antigen-presenting cells. These antigen-presenting cells then travel to regional lymph nodes where they present antigen to T cells, initiating or potentiating an antitumor immune response. Activated tumor-specific T cells can then traffic to areas of tumor to participate in immune-mediated tumor killing.

Figure 2

Figure 2

Irradiation modulates tumor-cell phenotype and increases immune recognition. Irradiation can cause (a) upregulation of chemokines and adhesion molecules, providing signals for T cells to come to areas of tumor, (b) upregulation of MHC molecules and tumor-associated antigens, making it easier for T cells to recognize tumor, and (c) upregulation of Fas and downregulation of regulatory T cells, making it easier for cytotoxic tumor-specific T cells to kill tumor.

Figure 3

Figure 3

Multiple mechanisms of synergy of radiation therapy and immunotherapy.

References

    1. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, Formenti SC. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58:862. -PubMed
    1. Demaria S, Formenti SC. Sensors of ionizing radiation effects on the immunological microenvironment of cancer. Int J Radiat Biol. 2007;83:819–825. -PubMed
    1. Sanda MG, Restifo NP, Walsh JC, Kawakami Y, Nelson WG, Pardoll DM, Simons JW. Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst. 1995;87:280–285. -PMC -PubMed
    1. Demaria S, Bhardwaj N, McBride WH, Formenti SC. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys. 2005;63:655. -PMC -PubMed
    1. Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 2008;15:3–12. -PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources